Earth Life Sciences Inc
Change company Symbol lookup
Select an option...
CLTS Earth Life Sciences Inc
CYBN Cybin Inc
LEN.B Lennar Corp
STLD Steel Dynamics Inc
GOEVW Canoo Equity Warrant Exp 21st Dec 2025 *W EXP 12/21/2025
GNBT Generex Biotechnology Corp
MFA MFA Financial Inc
GOOG Alphabet Inc
ADILW Adial Pharmaceuticals Equity Warrants Exp 31 July 2023 *W EXP 07/31/2023
MBDC Massachusetts Business Development Corp
Go


Based in Canada
Company profile

Earth Life Sciences Inc. is a healthcare company. The Company through its subsidiary, VIVA Health HK Limited (Viva Health), is engaged in providing health services primarily in the United States. Viva Health is focused on building a platform in the United States, which optimizes the functions of health care staff training management, health care service management and quality control, and providing a range of services in the United States, and particularly for aging Asian families. Through its artificial intelligence (AI), the Company seeks to assist in the customization and implementation of a software platform, which facilitates the delivery of onsite lifestyle services and well-being to families across the United States under the banner of VIVA USA. The Company through, Anhutong Healthcare Platform, provides a one stop smart healthcare service brand in the healthcare industry.

Closing Price
$0.0065
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Average)
Volume:
42,000

10-day average volume:
67,431
42,000

BioNTech stock sinks more than 8% after profit, revenue fall below expectations

6:18 am ET August 8, 2022 (MarketWatch)
Print

The U.S.-listed shares of Germany-based BioNTech SE (BNTX) sank 8.2% in premarket trading Monday, after the biotechnology company and Pfizer Inc. (PFE) partner in developing a COVID-19 vaccine reported second-quarter profit and revenue that fell below expectations but affirmed its full-year COVID-19 revenue outlook. Net income dropped to EUR1.67 billion ($1.70 bln), or EUR6.45 a share, from EUR2.79 billion, or EUR10.77 a share, in the year-ago period. The FactSet consensus for earnings per share was EUR7.08. Revenue fell to EUR3.20 billion ($3.26 billion) from EUR5.31 billion, missing the FactSet consensus of EUR3.88 billion. Under collaboration agreements with Pfizer and Shanghai Fosun Pharmaceutical Co. Ltd., BioNTech's commercial revenue included EUR1.99 billion gross profit share. "BioNTech believes the development of the pandemic remains dynamic, causing a re-phasing of orders and with this leading to fluctuations in quarterly revenues," the company said in a statement. "This revenue fluctuation caused by the re-phasing of orders is expected to remain over the rest of the financial year with an uptake in demand in key markets in the fourth quarter of 2022 related to the Omicron-adapted bivalent vaccine, subject to regulatory approval." The company affirmed its 2022 outlook for COVID-19 vaccine revenue of EUR13 billion to EUR17 billion. BioNTech's stock has rallied 34.5% over the past three months through Friday while Pfizer shares have gained 0.5% and the S&P 500 has tacked on 0.5%.

-Tomi Kilgore

	

(END) Dow Jones Newswires

August 08, 2022 06:18 ET (10:18 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.